Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures

Archives of Disease in Childhood

Volumn 97, Issue 6, 2012, Pages 569-572

  Lee, Soon Min ^a   Chung, Jae Yong ^a,b   Lee, Young Mock ^a   Park, Min Soo ^a,b   Namgung, Ran ^a   Park, Kook In ^a   Lee, Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; GENOMIC DNA; PHENOBARBITAL;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; LOADING DRUG DOSE; MALE; NEWBORN; PRIORITY JOURNAL; SEIZURE; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHENOBARBITAL; POLYMORPHISM, GENETIC; SEIZURES;

EID: 84862824522     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-300538     Document Type: Article

References (21)

1. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770:489-94. (Pubitemid 46136751)
2. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003;81:154-67. (Pubitemid 36470182)
3. Roots I, Gerloff T, Meisel C, et al. Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev 2004;36:617-38. (Pubitemid 39453066)
4. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004;45:1141-9. (Pubitemid 39238126)
5. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-76. (Pubitemid 351991390)
6. Goto S, Seo T, Murata T, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007;29:118-21. (Pubitemid 46279885)
7. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 2000;55:821-5. (Pubitemid 30201764)
8. Ratanasavanh D, Beaune P, Morel F, et al. Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology 1991;13:1142-51.
9. Allegaert K, Verbesselt R, Rayyan M, et al. Urinary metabolites to assess in vivo ontogeny of hepatic drug metabolism in early neonatal life. Methods Find Exp Clin Pharmacol 2007;29:251-6. (Pubitemid 47204045)
10. Ladona MG, Lindström B, Thyr C, et al. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991;32:295-302.
11. Ring JA, Ghabrial H, Ching MS, et al. Fetal hepatic drug elimination. Pharmacol Ther 1999;84:429-45.
12. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965-74. (Pubitemid 38263972)
13. Blake MJ, Castro L, Leeder JS, et al. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005;10:123-38. (Pubitemid 40215540)
14. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002;41:1077-94. (Pubitemid 35251856)
15. Touw DJ, Graafland O, Cranendonk A, et al. Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 2000;12:111-16.
16. Lindbom L, Pihlgren P, Jonsson EN, et al. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005;79:241-57. (Pubitemid 41196689)
17. Whyte MP, Dekaban AS. Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man. Drug Metab Dispos 1977;5:63-70. (Pubitemid 8040983)
18. Alonso Gonzalez AC, Ortega Valin L, Santos Buelga D, et al. Dosage programming of phenobarbital in neonatal seizures. J Clin Pharm Ther 1993;18:267-70. (Pubitemid 23235094)
19. Heimann G, Gladtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol 1977;12:305-10.
20. Pitlick W, Painter M, Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther 1978;23:346-50. (Pubitemid 8302192)
21. Allegaert K, van den Anker JN, Naulaers G, et al. Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2007;2:23-9. (Pubitemid 46723127)